when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
drugs
Imuldosa

drug

ustekinumab biosimilar

Marketedupdated 3mo ago

by Accord Biopharma Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 7

tagApproval12 co-mentions · 6 sources
drugIMULDOSA6 co-mentions · 3 sources
drugustekinumab6 co-mentions · 6 sources
drugYESINTEK6 co-mentions · 3 sources
drugSTELARA6 co-mentions · 6 sources
companyAccord Biopharma Inc3 co-mentions · 3 sources
companyBiocon Biologics Ltd3 co-mentions · 3 sources

indications

investigational

IBD (Crohn's + UC)

all catalysts(6)

approval · 6

IMULDOSA (USTEKINUMAB-SRLF) — FDA approval

ustekinumab biosimilar

YESINTEK (USTEKINUMAB-KFCE) — FDA approval

ustekinumab biosimilar

IMULDOSA (USTEKINUMAB-SRLF) — FDA approval

ustekinumab biosimilar

YESINTEK (USTEKINUMAB-KFCE) — FDA approval

ustekinumab biosimilar

IMULDOSA (USTEKINUMAB-SRLF) — FDA approval

ustekinumab biosimilar

YESINTEK (USTEKINUMAB-KFCE) — FDA approval

ustekinumab biosimilar

Trials studying ustekinumab biosimilar

phase3A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasiscompletedn=503

News(0)

no news has mentioned this drug yet

brand

Imuldosa

generic

ustekinumab-kfce

MOA

12.1 Mechanism of Action Ustekinumab products are human IgG1κ monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. In in vitro models, ustekinumab products were shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12Rβ1. The cytokines IL-12 and IL-23 have been implicated as important contributors to the chronic inflammation that is a hallmark of Crohn’s disease and ulcerative colitis. In animal models of colitis, genetic absence or antibody blockade of the p40 subunit of IL-12 and IL-23, the target of ustekinumab products, was shown to be protective.

indication

Psoriatic Arthritis

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 37m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?